Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.
Market Cap | 435.515 Million | Shares Outstanding | 148.64 Million | Avg 30-day Volume | 886.868 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.24 |
Price to Revenue | 7.9601 | Debt to Equity | 0.0 | EBITDA | -61.74 Million |
Price to Book Value | 1.9682 | Operating Margin | -177.015 | Enterprise Value | 96.252 Million |
Current Ratio | 5.131 | EPS Growth | 0.473 | Quick Ratio | 4.965 |
1 Yr BETA | 1.2062 | 52-week High/Low | 3.64 / 1.85 | Profit Margin | -191.3424 |
Operating Cash Flow Growth | 39.6686 | Altman Z-Score | -5.3563 | Free Cash Flow to Firm | -21.743 Million |
Earnings Report | 2023-03-02 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
41,000 | 2022-05-25 | 1 | |
|
41,000 | 2022-05-25 | 1 | |
|
41,000 | 2022-05-25 | 1 | |
|
41,000 | 2022-05-25 | 1 | |
|
41,000 | 2022-05-25 | 1 | |
|
41,000 | 2022-05-25 | 1 | |
HASTINGS DAVID C CHIEF FINANCIAL OFFICER |
|
285,000 | 2022-01-20 | 0 |
SOFIA MICHAEL J. CHIEF SCIENTIFIC OFFICER |
|
285,000 | 2022-01-20 | 0 |
MCELHAUGH MICHAEL J. CHIEF BUSINESS OFFICER |
|
325,850 | 2022-01-20 | 0 |
HOWARD ELIZABETH CHIEF COMPLIANCE OFFICER |
|
237,500 | 2022-01-20 | 0 |
PICCHIO GASTON CHIEF DEVELOPMENT OFFICER |
|
256,500 | 2022-01-20 | 0 |
COLLIER WILLIAM H. PRESIDENT AND CEO |
|
787,550 | 2022-01-20 | 0 |
|
38,847,462 | 2021-10-18 | 0 | |
|
22,000 | 2021-06-03 | 0 | |
|
0 | 2020-02-18 | 0 | |
|
0 | 2019-08-17 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
No longer subject to file | 2019-07-10 | 0 |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
|
No longer subject to file | 2019-07-10 | 0 | |
MURRAY MARK J. PRESIDENT AND CEO |
|
0 | 2019-03-01 | 0 |
|
16,013,540 | 2019-01-01 | 0 | |
VANDENENDEN KOERT CHIEF ACCOUNTING OFFICER |
|
0 | 2018-12-11 | 0 |
|
0 | 2018-06-19 | 0 | |
|
0 | 2018-06-19 | 0 | |
SYMONDS WILLIAM T. CHIEF DEVELOPMENT OFFICER |
|
0 | 2018-04-16 | 0 |
LUTWYCHE PETER FORMER CHIEF TECH. OFFICER |
|
No longer subject to file | 2018-04-11 | 0 |
COUSINS BRUCE EXEC VO & CFO |
|
No longer subject to file | 2018-02-16 | 0 |
|
0 | 2018-01-12 | 0 | |
|
16,013,540 | 2017-09-06 | 0 | |
|
16,013,540 | 2017-07-01 | 0 | |
|
0 | 2017-06-21 | 0 | |
ABRAMS MICHAEL J. MANAGING DIRECTOR |
|
No longer subject to file | 2016-09-30 | 0 |
KOWALSKI MARK SR VP & CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2016-09-30 | 0 |
VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC |
|
16,013,540 | 2016-07-08 | 0 |
|
16,013,540 | 2016-07-08 | 0 | |
HIGGINS PATRICK T. CHIEF BUSINESS OFFICER |
|
No longer subject to file | 2016-04-30 | 0 |
|
No longer subject to file | 2015-03-04 | 0 | |
|
No longer subject to file | 2015-03-04 | 0 | |
BRENNAN PAUL A. SR VP, BUSINESS DEVELOPMENT |
|
No longer subject to file | 2015-03-04 | 0 |
|
No longer subject to file | 2015-03-04 | 0 | |
|
No longer subject to file | 2015-03-04 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 22:15:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 21:45:04 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 21:15:04 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 20:45:03 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 20:15:04 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 19:45:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 19:15:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 18:45:04 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 18:15:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 17:45:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 17:15:04 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 16:45:03 UTC | 3.8088 | 0.5112 | 6400000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 16:15:03 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 15:45:03 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 15:15:04 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 14:45:04 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 14:15:03 UTC | 3.8088 | 0.5112 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 13:45:03 UTC | 3.8149 | 0.5051 | 6200000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 13:15:03 UTC | 3.8149 | 0.5051 | 6300000 |
ARBUTUS BIOPHARMA CORP ABUS | 2023-01-27 12:45:03 UTC | 3.8149 | 0.5051 | 6300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ABUS | -400.0 shares, $-764.0 | 2022-09-30 | N-PORT |